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Introduction
============

Cardiovascular disease (CVD) is the number one cause of death throughout the world^[@bib1])^. The World Health Organization (WHO) reported that an estimated 17.5 million people died from CVD in 2012, which represented 31% of global deaths. Among these deaths, an estimated 7.4 million people died due to coronary artery disease (CAD), while 6.7 million died due to stroke. In contrast, in 2000, an estimated 6 million died due to CAD, while 5.7 million died due to stroke. Accordingly, the number of deaths caused by CVDs has increased over the past decade. It is therefore essential to elucidate the endothelial functions that play a key role in the pathophysiology of atherosclerosis.

The endothelium is not only a passive barrier but also an active transducer, as it participates in a variety of paracrine factors that act locally in the blood vessel walls and lumen^[@bib2])^. Under healthy conditions, the endothelium produces a wide range of factors that regulate vascular tone, adhesion of circulating blood cells to the vessel wall, thrombus formation, smooth muscle cell proliferation, and vessel wall inflammation. However, under the existence of risk factors such as hypercholesterolemia, hypertension, smoking, and diabetes mellitus, the phenotype of the endothelium may be altered such that it accelerates inflammation, thrombosis, vasoconstriction, and the formation of atherosclerotic lesions^[@bib3])^. This maladaptive endothelial phenotype appears in early atherosclerosis and is associated with the classical cardiovascular risk factors.

The flow-mediated dilation (FMD) test has emerged as a major non-invasive tool for assessing endothelial function in clinical settings^[@bib4]--[@bib6])^. FMD acts as a marker of Nitric Oxide (NO)-mediated endothelium-dependent vasodilator function. Impaired FMD is an indicator of endothelial dysfunction and is reported to be a predictor of future CVD^[@bib7],\ [@bib8])^. The FMD value has also been found to be a predictor of changes in the levels of carotid plaque, independent of the classical cardiovascular risk factors^[@bib9])^. Because endothelial dysfunction is a systemic process, an impaired FMD measurement in the forearm indicates the presence of systemic endothelial dysfunction. Thus, impaired FMD is an early marker of atherosclerosis. Notably, FMD has been shown to be strongly correlated with coronary endothelial function^[@bib10])^.

Cilostazol is a unique antiplatelet drug that selectively and reversibly targets phosphodiesterase III (PDE-III)^[@bib11])^. PDE-III is usually present in the platelets, endothelial cells, and smooth muscle cells, where it increases cyclic adenosine monophosphate concentrations, resulting in vasodilation. It also increases sensitivity to endogenous vasodilators, such as prostaglandins, and inhibits both the primary and secondary platelet aggregation induced by collagen, adenosine diphosphate (ADP), arachidonic acid, and epinephrine. Cilostazol is also reported to reduce angiographic restenosis after percutaneous transluminal angioplasty with provisional nitinol stenting for femoropopliteal lesions^[@bib12])^. Additionally, the clinical outcomes of patients with acute myocardial infarction who are treated with cilostazol, in addition to conventional dual antiplatelet therapy, are favorable in comparison to those who are treated with conventional dual antiplatelet therapy^[@bib13])^.

Aim
===

Although FMD has been well assessed and cilostazol has been widely used in patients with atherosclerosis, the effect of cilostazol on endothelial function as assessed by FMD has not been elucidated in patients with coronary artery disease. The present study was therefore performed to investigate the effect of cilostazol on endothelial function as assessed by FMD in patients with coronary artery disease.

Methods
=======

Study Subjects
--------------

This study was a prospective, open-label, randomized trial. Patients were eligible if they had angina requiring percutaneous coronary intervention (PCI) within two months prior to enrollment. The exclusion criteria included heart failure (New York Heart Association functional class II---IV), left ventricular ejection fraction \< 40%, end-stage renal failure requiring hemodialysis, atrial fibrillation, active systemic inflammatory disease, collagen disease, active hepatic disease, malignancy, the usage of anticoagulation therapy, and a history of acute myocardial infarction within the last 3 months. A total of 51 eligible patients were prospectively recruited from September 2010 to March 2012 at Showa University Fujigaokoa Hospital. The patients were randomly assigned to either the Cilostazol(+) group (with cilostazol) or the Cilostazol(−) group (without cilostazol). On top of conventional dual antiplatelet therapy (DAPT) with aspirin (100 mg/day) and clopidogrel (75 mg/day)/ticlopidine (200 mg/day), the patients in the Cilostazol(+) group (*n* = 27) were given cilostazol (100 mg/day). The patients in the Cilostazol(−) group (*n* = 24) were not given cilostazol. The patients\' endothelial function and blood biochemistry were assessed at enrollment and at 6--9 months after the start of the study. In all patients, coronary risk factors were controlled according to Japanese circulation guidelines^[@bib14],\ [@bib15])^. Clinical follow-up visits were scheduled every 1--3 months. At the time of enrollment and 6 to 9 months after enrollment, all of the patients underwent endothelial function and blood biochemistry assessments. Routine angiographic follow-up was not mandatory. All adverse clinical events were assessed.

This study was approved by the Institutional Ethics Review Committee. Written informed consent was obtained from each patient before participation. This study was registered under the UMIN protocol registration system (ID UMIN 000004065).

The Assessment of Endothelial Function
--------------------------------------

All subjects were instructed to fast after dinner on the day before the assessment and to refrain from smoking and ingesting any alcohol or caffeine during the study period. All assessments were conducted from 9 to 10:30 AM. All subjects rested for at least 15 min in a seated position in a quiet, dark, air-conditioned room before each FMD assessment. A longitudinal image of the brachial artery was recorded at baseline using an ultrasound with a 10M-Hz linear array transducer probe (UNEX, Nagoya, Japan). A forearm-cuff was then inflated for 5 min at 50 mmHg above the SBP (systolic blood pressure) just before the FMD assessment. After deflation of the cuff, the diastolic diameter of the brachial artery was semi-automatically recorded continuously for 2 min. The FMD was then estimated as the percent change in vessel diameter from baseline to maximum dilatation during reactive hyperemia. Because FMD is highly dependent on the baseline diameter of the vessel, we also compared the baseline and maximal diameters in each group. Experienced technicians were blinded to the clinical data of the study participants. Intra- and inter-observer correlation coefficients for FMD were considerably high (0.99 and 0.92, respectively).

The Assessment of Angiography
-----------------------------

Lesion characteristics were assessed according to AHA classification. Drug eluting stent (DES) usage, stent diameter and length, the number of stents, and the number of stents per vessel were described. Target lesion revascularization (TLR) and target vessel revascularization (TVR) were assessed.

Blood Biochemistry
------------------

Blood samples were collected from all patients after overnight fasting at baseline and at 6--9 months. High-sensitive C-reactive protein (CRP) tests were conducted by SRL, Inc (Tokyo, Japan). Health Sciences Research Institute, Inc. (Yokohama, Japan) assessed the levels of brain natriuretic peptide (BNP). All other biochemical analyses were performed inhouse.

Statistical Analyses
--------------------

All statistical analyses were performed using the JMP software program (JMP, Version 11; SAS Institute Inc., NC, USA). The sample size was calculated by a power analysis using preliminary data with the following assumptions: a Type I error of 0.05 (2-tailed), 80% power, a mean increase in FMD of 10% in the Cilostazol(+) group, a mean increase in FMD of 0% in the Cilostazol(−) group, and a standard deviation of 10% in each group. It was determined that a minimum of 17 patients (total of 34 patients) would be required to obtain 80% power in detecting a difference in the %change of FMD from enrollment to 6--9 months.

The patients\' age, laboratory data, baseline brachial artery diameter, and maximal brachial artery diameter were expressed as the mean ± SD. The stent diameter, stent length, stent number, stent number per lesion, and FMD were expressed as the median (interquartile range). Comparisons between continuous variables were analyzed using either the *t*-test or Wilcoxon\'s rank sum test, as appropriate. The categorical variables were analyzed using the chi-square test. The enrollment and follow-up data were compared using a paired *t*-test or Wilcoxon\'s singed rank test, as appropriate. *P* values of \< 0.05 were considered to be statistically significant.

Results
=======

Patient disposition is summarized in **[Fig. 1](#F1){ref-type="fig"}**. Fifty-one patients were randomly assigned to the Cilostazol(+) (*n* = 27) and Cilostazol(−) groups (*n* = 24). All of the patients survived for the duration of the study period. In the Cilostazol(+) group, cilostazol treatment was stopped in 2 patients due to palpitation and 1 patient due to minor bleeding; we could not follow 2 patients due to poor compliance. In the Cilosatazol(−) group, we could not follow 2 patients due to poor compliance. There was no single major bleeding episode. Accordingly, the final analysis included 22 patients in the Cilostazol(+) group and 22 patients in the Cilostazol(−) group.

![Patient disposition flow chart](jat-23-1168-g001){#F1}

**[Table 1](#T1){ref-type="table"}** shows the baseline clinical characteristics of the study patients. There were no significant differences in terms of age, gender, hypertension, hyperlipidemia, diabetes, chronic kidney disease, current smoking status, cerebrovascular disease, peripheral artery disease, previous myocardial infarction or unstable angina pectoris. There were no statistically significant differences between the two groups with regard to the use of major medications, including angiotensin converting enzyme inhibitor (ACE-I)/angiotensin II receptor blockers (ARBs), *β*-blockers, calcium channel blockers (CCB), statins and nitrate/nicorandil.

###### The baseline clinical characteristics of patients

                            Overall (*n* = 44)   Cilostazol (+) (*n* = 22)   Cilostazol (−) (*n* = 22)   *P* value
  ------------------------- -------------------- --------------------------- --------------------------- -----------
  Age, years                67 ± 8               67 ± 7                      66 ± 10                     0.81
  Male, *n* (%)             34 (77.3%)           16 (72.7%)                  18 (81.8%)                  0.47
  Hypertension, *n* (%)     32 (72.7%)           18 (81.8%)                  14 (63.6%)                  0.18
  Hyperlipidemia, *n* (%)   38 (86.4%)           19 (86.4%)                  19 (86.4%)                  1.00
  Diabetes, *n* (%)         19 (43.2%)           10 (45.5%)                  9 (40.9%)                   0.76
  CKD, *n* (%)              5 (11.4%)            1 (4.6%)                    4 (18.1%)                   0.15
  Current Smoker, *n* (%)   13 (29.6%)           5 (22.7%)                   8 (36.3%)                   0.32
  CVD, *n* (%)              2 (4.6%)             0                           2 (9.1%)                    0.15
  PAD, *n* (%)              1 (2.3%)             0                           1 (4.6%)                    0.31
  Previous MI               10 (22.7%)           5 (22.7%)                   5 (22.7%)                   1.00
  UAP, *n* (%)              16 (38.4%)           6 (37.5%)                   10 (45.5%)                  0.21
  Medication, *n* (%)                                                                                    
      ACE-I/ARB             26 (59.1%)           14 (63.6%)                  12 (54.6%)                  0.54
      *β*-blokers           13 (29.6%)           4 (18.2%)                   9 (40.9%)                   0.10
      CCB                   19 (43.2%)           11 (50.0%)                  8 (36.4%)                   0.36
      Statin                40 (90.9%)           19 (86.4%)                  21 (95.5%)                  0.29
      Nitrate/Nicorandil    7 (15.9%)            5 (22.7%)                   2 (9.1%)                    0.22

The data are shown as the mean ± SD or *n* (%). CKD, chronic kidney disease; CVD, cerebrovascular disease; PAD, peripheral artery disease; Previous MI, previous myocardial infarction; EF, ejection fraction; UAP, unstable angina pectoris; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium-channel blocker.

The procedural characteristics are shown in **[Table 2](#T2){ref-type="table"}**. We did not observe any significant differences in the number of treated lesions, type B2 or C lesions, target vessel location, indications of *de novo* lesions, indications of in-stent restenosis, prevalence of previous PCI, prevalence of previous CABG or drug eluting stent (DES) usage. Regarding stent usage, the diameter, length, number of stents, and number of stents per lesion were similar. At 6--9 months, target vessel and target lesion revascularization was comparable between the two groups.

###### The characteristics of the procedures

                                       Overall (*n* = 44)   Cilostazol (+) (*n* = 22)   Cilostazol (−) (*n* = 22)   *P* value
  ------------------------------------ -------------------- --------------------------- --------------------------- -----------
  Number of treated lesions, *n* (%)   1.0 (1.0--2.0)       1.0 (1.0--2.0)              1.0 (1.0--2.0)              0.87
  Target Vessel, *n* (%)                                                                                            
      LMT                              2 (4.6%)             1 (4.6%)                    1 (4.6%)                    1.00
      RCA                              18 (40.9%)           10 (45.5%)                  8 (36.4%)                   0.54
      LAD                              32 (72.7%)           16 (72.7%)                  16 (72.7%)                  1.00
      LCX                              14 (31.8%)           6 (27.3%)                   8 (36.4%)                   0.52
  *De novo, n* (%)                     41 (93.2%)           22 (100.0%)                 19 (86.4%)                  0.07
  ISR, *n* (%)                         8 (18.2%)            4 (18.2%)                   4 (18.2%)                   1.00
  Type B2 or C, *n* (%)                12 (27.3%)           6 (27.3%)                   6 (27.3%)                   1.00
  Previous PCI, *n* (%)                11 (25%)             7 (31.8%)                   4 (18.2%)                   0.30
  Previous CABG, *n* (%)               1 (2.3%)             1 (4.6%)                    0 (0%)                      0.31
  DES usage, *n* (%)                   35 (79.6%)           19 (86.4%)                  16 (72.8%)                  0.26
  Stent diameter, mm                   3.0 (3.0--3.5)       3.0 (2.75--3.5)             3.5 (3--3.5)                0.48
  Stent length, mm                     18 (15--23)          18.0 (15.0--23.0)           18.0 (14.0--23.0)           0.78
  Stent number, *n*                    1.0 (1.0--2.0)       1.0 (1.0--2.0)              1.5 (1.0--2.3)              0.66
  Stent number per vessel, *n*         1.0 (1.0--2.0)       1.0 (1.0--2.0)              1.0 (1.0--2.0)              0.62
  TVR (6--9 months), *n* (%)           9 (20.5%)            5 (22.7%)                   4 (18.2%)                   0.71
  TLR (6--9 months), *n* (%)           7 (15.9%)            4 (18.2%)                   3 (13.6%)                   0.68

Data are *n* (%) or median and (interquartile range). LMT, left main trunk; RCA, right coronary artery; LAD, left anterior descending; LCX, left circumflex; ISR, in-stent restenosis; Previous PCI, previous percutaneous coronary intervention; Previous CABG, previous coronary artery bypass graft; DES, drug-eluting stent; TLR, target lesion revascularization; TVR target vessel revascularization.

**[Table 3](#T3){ref-type="table"}** shows the laboratory data at enrollment and at 6--9 months in each group. Upon enrollment, all laboratory data were comparable between the two groups. There were no significant differences in serum creatinine, LDL cholesterol, triglyceride, or glycohemoglobin levels over time in either group. In both groups, the level of HDL cholesterol increased over time; a significant difference was only observed in the Cilostazol(−) group. The LDL/HDL ratio significantly decreased over time in both groups. BNP decreased significantly in the Cilostazol(+) group. BNP also decreased in the Cilostazol(−) group, but these data were not statistically significant. High-sensitive CRP levels were assessed in a limited number of patients (Cilostazol(+) group, *n* = 19; Cilostazol(−) group, *n* = 15). In these patients, high-sensitive CRP levels decreased from 0.29 ± 0.74 mg/dl to 0.12 ± 0.15 mg/dl in the Cilostazol(+) group, but these data were not significant (*P* = 0.21), while there was a non-significant increase from 0.19 ± 0.31 mg/dl to 0.32 ± 0.73 mg/dl in the Cilostazol(−) group (*P* = 0.64).

###### Laboratory data of patients at enrollment and at 6--9 Months

                           Cilostazol (+) (*n* = 22)                 Cilostazol (−) (*n* = 22)                               
  ------------------------ --------------------------- ------------- --------------------------- ------------- ------------- ------
  Cre, mg/dl               0.81 ± 0.14                 0.82 ± 0.17   0.33                        0.88 ± 0.24   0.87 ± 0.27   0.37
  LDL cholesterol, mg/dl   110 ± 27                    103 ± 24      0.30                        102 ± 35      90 ± 28       0.16
  HDL cholesterol, mg/dl   54 ± 18                     58 ± 20       0.07                        50 ± 10       53 ± 11       0.01
  LDL/HDL ratio            2.2 ± 1.1                   2.0 ± 0.9     0.01                        2.1 ± 0.8     1.8 ± 0.8     0.02
  TG, mg/dl                134 ± 52                    130 ± 50      0.56                        142 ± 93      156 ± 82      0.53
  Hb A1c, %                6.4 ± 0.8                   6.6 ± 1.1     0.31                        6.7 ± 1.3     6.6 ± 1.2     0.87
  BNP, pg/ml               63 ± 121                    24 ± 19       0.01                        69 ± 96       62 ± 90       0.68

The data are shown as the mean ± SD. Cre, serum creatine; TG, triglyceride; Hb A1c, hemoglobin A1c; BNP, brain natrium peptide.

**[Table 4](#T4){ref-type="table"}** shows the results of FMD, baseline brachial artery diameter, maximal brachial artery diameter, systolic blood pressure, diastolic blood pressure, and heart rate at each time point. The FMD of both the Cilostazol(+) and Cilostazol(−) groups remained similar at 5.2 (interquartile range:3.8--8.5) to 5.4 (interquartile range:4.2--6.7) (*P* = 0.29) and 4.9 (interquartile range:4.0--7.0) to 5.0 (interquartile range: 3.6--6.4) (*P* = 0.38), respectively. The percent change in FMD was −6.9% (interquartile range:−23.5--16.6%) in the Clisotazol(+) group and +7.0% (interquartile range:−21.8--49.6%) in the Cilostazol(−) group and was not statistically significant (*P* = 0.34). Although the FMD did not change significantly in either group, the baseline brachial artery diameter and maximal brachial artery diameter increased in the Cilostazol(−) group (baseline: 4.2 ± 0.7 to 4.4 ± 0.7, *P* = 0.18; maximal: 4.5 ± 0.7 to 4.6 ± 0.7, *P* = 0.22) and decreased in the Cilostazol(+) group (baseline: 4.1 ± 0.6 to 3.9 ± 0.5, *P* = 0.10; maximal: 4.3 ± 0.7 to 4.1 ± 0.5, *P* = 0.05). There were statistically significant differences in the percent change (**[Fig. 2](#F2){ref-type="fig"}**) in the baseline diameter (Cilostazol(+): +3.7 ± 9.8% vs. Cilostazol(−): −3.8 ± 12.2%) and in the maximal diameter (Cilostazol(−): −3.1 ± 8.9% vs. Cilostazol(−): −4.4 ± 12.0%). The trends in blood pressure and heart rate were similar in both groups.

###### FMD (flow-mediated dilation), baseline diameter of brachial artery, maximal diameter of brachial artery, SBP (systolic blood pressure), DBP (diastolic blood pressure), and HR (heart rate) at enrollment and 6.9 months thereafter

                          Cilostazol (+) (*n* = 22)                    Cilostazol (−) (*n* = 22)                                     
  ----------------------- --------------------------- ---------------- --------------------------- ---------------- ---------------- ------
  FMD, %                  5.2 (3.8--8.5)              5.4 (4.2--6.7)   0.29                        5.0 (3.6--6.4)   4.9 (4.0--7.0)   0.38
  baseline diameter, mm   4.2 ± 0.7                   4.4 ± 0.7        0.18                        4.1 ± 0.6        3.9 ± 0.5        0.10
  maximal diameter, mm    4.5 ± 0.7                   4.6 ± 0.7        0.22                        4.3 ± 0.7        4.1 ± 0.5        0.05
  SBP, mmHg               125 ± 16                    131 ± 16         0.15                        125 ± 17         130 ± 19         0.28
  DBP, mmHg               69 ± 7                      73 ± 11          0.21                        69 ± 13          70 ± 10          0.74
  HR, n/min               67 ± 11                     65 ± 12          0.64                        70 ± 10          67 ± 8           0.20
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Discussion
==========

To the best of our knowledge, this is the first study to investigate the effect of cilostazol on endothelial function as assessed by FMD in patients with coronary artery disease. We did not find cilostazol to affect FMD. However, there was a greater rate of change in the baseline and maximal brachial artery diameters in the Cilostazol(+) group between enrollment and follow-up in comparison to the Cilostazol(−) group. This dilation of brachial artery diameter is consistent with its well-described vasodilator effect and may be of potential benefit to patients with cardiovascular disease, especially those with peripheral artery disease.

There are several previous reports (**[Supplemental Table 1](#T5){ref-type="table"}**) that have studied the effects of cilostazol on endothelial function as assessed by FMD; however, these reports did not involve patients with coronary artery disease and the durations of treatment were not as long as our study^[@bib16]--[@bib20])^. Three reports^[@bib16]--[@bib18])^ investigating younger smokers found that 2 weeks of cilostazol treatment resulted in FMD improvement. These studies^[@bib16]--[@bib18])^ indicated that younger smokers are more likely to respond to cilostazol treatment. One report^[@bib19])^ examined patients with silent cerebral lacunar infarction and hypercholesterolemia who received a combination of probucol and cilostazol for four weeks, and found that treatment resulted in FMD improvement. Although these cases showed similar clinical characteristics, the FMD values at enrollment were much lower than those of our study and the patient\'s LDL cholesterol levels at enrollment were much higher (134 ± 27 mg/dl in the Probucol + Cilostazol group, 136 ± 30 mg/dl in the aspirin group) than in our study (108 ± 28 mg/dl in the Cilostazol(+) group, 102 ± 32 mg/dl in the Cilostazol(−) group). Thus, several factors existed that could be improved by more aggressive drug therapy. In one report^[@bib20])^ Raynaud\'s syndrome patients who received cilostazol for 6 weeks showed no FMD improvement. However, similar to our study, the patients showed a significant increase in brachial artery diameter.

The addition of cilostazol, on top of conventional dual antiplatelet therapy, has been reported to be beneficial for patients with coronary artery disease who require coronary stents; however, these reports mainly measure improvement by the reduction of instent restenosis^[@bib21],\ [@bib22])^. On the other hand, there are reports that show that the addition of cilostazol on top of conventional dual antiplatelet therapy did not result in better clinical outcomes in patients with coronary artery disease who required coronary stents in comparison to conventional dual antiplatelet therapy^[@bib23],\ [@bib24])^. Although the endpoints of these studies differed from our own, the patient demographics were quite similar. Thus, with the knowledge of these conflicting data, that cilostazol did not improve the FMD values of the patients in our study, was not entirely unexpected.

Unlike patients with coronary artery disease, patients with peripheral artery disease are more likely to benefit from cilostazol. Cilostazol has been reported to reduce not only the risk of restenosis but also the risk of amputation in patients with cardiovascular disease^[@bib25])^. The vasodilatory effect of cilostazol that we observed in our study can be beneficial to such patients. However, in spite of these effects, there is not enough evidence to support that the administration of cilostazol can reduce mortality.

Cilostazol is contraindicated for patients with severe heart failure since other PDE inhibitors such as milrinone^[@bib26])^ and vesnarinon^[@bib27])^, which are used as inotropic agents for patients with severe heart failure, have been shown to be associated with a worse clinical outcome. However, in the present study, there was a significant decrease in BNP levels in the Cilostazol(+) group. This result indicates the possible utility of cilostazol in the treatment of patients with coronary artery disease but without heart failure.

Study Limitations
-----------------

There are several limitations associated with this study. First, this was not a double-blind study and there was no placebo, although the endothelial functions were assessed in a blinded manner. Second, FMD is highly dependent on the baseline brachial diameter^[@bib28])^; a large baseline vessel diameter is correlated with a low FMD value. As a result, the vasodilation effect of cilostazol likely affected FMD readings. Third, the study was performed at a single center with a small study population and we did not administer the maximum dose of cilostazol. However, in the present study, the addition of cilostazol did not result in any improvement in FMD. The percent change in FMD was somewhat worse in the Cilostazol(+) group but did not reach statistical significance. We are therefore of the opinion that it is very difficult to show that the addition of cilostazol results in an improvement in FMD, even if we increase the number of cases.

Conclusion
==========

Although cilostazol did not affect FMD in patients with coronary artery disease, the increased baseline and maximal brachial artery diameter and the significant difference in the rate of change, suggests that cilostazol may be beneficial for patients with cardiovascular disease.

We thank Fuyuki Asano, Yuki Honda, Tomomi Futagawa, Misako Mori, Mamoru Hatakeyama and the entire cardiology staff and also the physiological laboratory staff for their valuable support.

Disclosures
===========

The author has received honorarium from Terumo R&D, Goodman CO., LTD and Abbott Vascular Japan.

###### Comparisons with previous publications

  Study demographic                 FMD data in cilostazol group                                                                                                                                                                                                                                                         
  --------------------------------- ----------------------------------------------------------- -------------------------------------- --------------------------- ----------------------------------------- --------------------------------------------------------------------- ----------------- ------------------- ---------
  Mori *et al.*                     Coronary artery disease                                     22                                     67 ± 7                      6--9 months                               Cilostazol (100 mg/day) and conventional dual antiplatelet theraphy   5.2 (3.8--8.5)    5.4 (4.2--6.7)      0.29
                                                                                                                                                                                                                                                                                                                         
                                                                                                22                                     66 ± 10                     Conventional dual antiplatelet theraphy   5.0 (3.6--6.4)                                                        4.9 (4.0--7.0)    0.38                
                                                                                                                                                                                                                                                                                                                         
  Oida *et al.*                     Smoker                                                      20                                     38 ± 5.2                    2 weeks                                   Cilostazol (150 mg/day)                                               4.2 ± 1.2         7.8 ± 3.5           0.003
                                                                                                                                                                                                                                                                                                                         
  Kim *et al.*                      Smoker                                                      20                                     29.1 ± 1.9                  2 weeks                                   Cilostazol (200 mg/day)                                               8.0 ± 2.1         12.2 ± 5.1          0.003
                                                                                                                                                                                                                                                                                                                         
                                    Non-smoker                                                  10                                     28 ± 1.1                    12.0 ± 4.5                                16.1 ± 3.7                                                            0.041                                 
                                                                                                                                                                                                                                                                                                                         
  Jeong *et al.*                    Smoker                                                      20 (cross over with 1 week interval)   29 ± 2                      2 weeks                                   Cilostazol (200 mg/day)                                               7.7 ± 1.9         8.8 ± 2.0           0.016
                                                                                                                                                                                                                                                                                                                         
                                                                                                                                       Sarpogrelate (200 mg/day)   7.4 ± 1.9                                 8.8 ± 1.9                                                             0.021                                 
                                                                                                                                                                                                                                                                                                                         
  Takae *et al.*                    Silent cerebral Lacunar infarcts and hypercholesterolemia   17                                     72 ± 7                      4 weeks                                   Cilostazol (200 mg/day) and Probucol (500 mg/day)                     2.69 ± 1.51       3.53 ± 1.69         \< 0.05
                                                                                                                                                                                                                                                                                                                         
                                    17                                                          72 ± 8                                 Aspirin (100 mg/day)        2.63 ± 1.48                               2.92 ± 1.39                                                           NS                                    
                                                                                                                                                                                                                                                                                                                         
  Rajagopalan *et al.*              Raynaud\'s syndrome (primary)                               19                                     47 ± 12                     6 weeks                                   Cilostazol (200 mg/day)                                               4.06 (2.5--6.1)   −0.77 (−2.4--3.5)   NS
                                                                                                                                                                                                                                                                                                                         
  Placebo                           Not available                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                         
  Raynaud\'s syndrome (secondary)   20                                                          41 ± 13                                Cilostazol (200 mg/day)     2.23 (0.05--6.3)                          2.95 (1.7--7.4)                                                       NS                                    
                                                                                                                                                                                                                                                                                                                         
  Placebo                           Not available                                                                                                                                                                                                                                                                        

FMD = flow-mediated dilation.
